retatrutide peptide clinical trial results Lilly orforglipron oral GLP-1 phase 3 weight loss Retatrutide Results: 24% Weight Loss
Description
The new drug combination was tested in 1,663 adults with type 2 diabetes that had an average BMI of 31 and average HbA1c of 67 mmol/mol (8.3%)
This unique combination makes Retatrutide of particular interest within research on energy management, metabolism and weight regulation
A 2023 survey shows that 4% of Americans already follow the keto diet
Intrigued by what he had found, Raufman continued to probe the salivary peptides to better understand how they worked
It needs to be monitored
Chen J, Xie JJ, Shi KS, et al
